NEONC TECHNOLOGIES HOLDINGS (NTHI) Stock News
NASDAQ:NTHI - Nasdaq - US64051A1016 - Common Stock - Currency: USD
NTHI Latest News, Press Relases and Analysis
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc...
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
الرئيس التنفيذي لشركة NeOnc Technologies Holdings, Inc.، Amir Heshmatpour، يتولى دورًا قياديًا مُوسّعًا بصفته الرئيس الجديد للشركة
كالاباساس، كاليفورنيا،, April 10, 2025 (GLOBE NEWSWIRE) -- أعلنت اليوم شركة NeOnc Technologies Holdings, Inc. (المدرجة في بورصة NASDAQ تحت الرمز NTHI)،...
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company...
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company...
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical...
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical...
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market
-- Anticipated Listing March 26, Nasdaq Global Market: Symbol NTHI --
NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market
-- Anticipated Listing March 26, Nasdaq Global Market: Symbol NTHI --...
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors
Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology...
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors
Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
Delshad adds broad management and financial expertise to the NeOnc team...
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
Delshad adds broad management and financial expertise to the NeOnc team
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
Almonawer adds broad financial expertise to the NeOnc team...
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
Almonawer adds broad financial expertise to the NeOnc team
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team...
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team
NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
Dr. Medvec adds extensive knowledge of high-stakes issues including mergers and acquisitions and partnerships to the NeOnc team
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous...
NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award
Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System...
NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award
Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough...
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award
NeOnc upsizes proposed IPO to $75M from $50M (Pending:NTHI)
NeOnc Technologies (NTHI) has upsized its proposed IPO to $75M. The brain cancer therapy developer aims to list its shares on Nasdaq under symbol NTHI.